UTHR:NASDAQUnited Therapeutics Corporation Analysis

United Therapeutics (UTHR) is trading at $569.18, comfortably above its 20‑day SMA of $575.19 and well above the 200‑day SMA of $460.99, indicating a bullish long‑term trend. However, the price sits just above the near‑term support level of $560.16 and below the resistance of $609.35, while the MACD has turned bearish (histogram –1.40) and RSI hovers at a neutral 50.6, suggesting short‑term momentum may be weakening. The stock’s beta of 0.21 and a 30‑day volatility of 44.7% point to low systematic risk but high price swings, and volume is on a decreasing trend, which could exacerbate price instability. Fundamentally, UTHR boasts strong profitability (gross margin 86.6%, operating margin 41.7%, profit margin 40.6%) and a solid balance sheet with $2.15 bn cash and zero debt, yet revenue contracted by 1.6% YoY and the latest earnings missed consensus ($5.82 EPS vs $6.73 estimate). The DCF fair value of $229 is far below the market price, flagging the stock as potentially overvalued, though analysts’ targets (median $660) imply a 13% upside and the forward PE of 16.6 is attractive relative to the current PE of 21.0 and the industry average of 26.7.
The recent news adds mixed signals: the Q1 earnings miss and a $5.5 M insider sale by CEO Martine Rothblatt raise short‑term concerns, while the upcoming earnings release on May 6 may clarify the trajectory. With an “Extreme Greed” sentiment index (90.9) and a buy recommendation from 13 analysts, the broader outlook remains positive, especially for investors focused on the company’s high margins, cash generation, and pipeline in pulmonary arterial hypertension and regenerative medicine.